BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27385428)

  • 1. Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.
    Wang A; Richhariya A; Gandra SR; Calimlim B; Kim L; Quek RG; Nordyke RJ; Toth PP
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27385428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.
    McGowan MP
    J Clin Lipidol; 2013; 7(3 Suppl):S21-6. PubMed ID: 23642325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures.
    van Buuren F; Kreickmann S; Horstkotte D; Kottmann T; Mellwig KP
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):24-30. PubMed ID: 22528135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group.
    Gordon BR; Kelsey SF; Bilheimer DW; Brown DC; Dau PC; Gotto AM; Illingworth DR; Jones PH; Leitman SF; Prihoda JS
    Am J Cardiol; 1992 Oct; 70(11):1010-6. PubMed ID: 1414897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.
    van Wijk DF; Sjouke B; Figueroa A; Emami H; van der Valk FM; MacNabb MH; Hemphill LC; Schulte DM; Koopman MG; Lobatto ME; Verberne HJ; Fayad ZA; Kastelein JJ; Mulder WJ; Hovingh GK; Tawakol A; Stroes ES
    J Am Coll Cardiol; 2014 Oct; 64(14):1418-26. PubMed ID: 25277610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia.
    Streicher J; Valent P; Schmidt H; Sengölge G; Wagner O; Strobl W; Hörl WH; Derfler K
    J Investig Med; 1999 Sep; 47(8):378-87. PubMed ID: 10510590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Olbricht CJ; Schoeppe E
    Ther Apher; 1997 Aug; 1(3):242-8. PubMed ID: 10225746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia.
    Palcoux JB; Meyer M; Jouanel P; Vanlieferinghen P; Malpuech G
    Ther Apher; 2002 Apr; 6(2):136-9. PubMed ID: 11982954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
    Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
    Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia.
    Thompson GR; Kitano Y
    Ther Apher; 1997 Feb; 1(1):13-6. PubMed ID: 10225774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia.
    Vella A; Pineda AA; O'Brien T
    Mayo Clin Proc; 2001 Oct; 76(10):1039-46. PubMed ID: 11605688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
    Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
    J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating progenitor cells in patients with familial hypercholesterolemia.
    Sandesara PB; Ramjee V; Ghasemzadeh N; Guo Y; Bhatia N; Li Q; Vaughn L; Nell-Dybdahl C; Waller EK; Mahar EA; Brigham K; Wilson PWF; Quyyumi A; Le NA; Sperling LS
    J Clin Apher; 2018 Jun; 33(3):404-408. PubMed ID: 29114919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
    Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
    J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.